NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis → Warren Buffett & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free GMAB Stock Alerts $27.77 -0.78 (-2.73%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$27.75▼$28.1150-Day Range$27.46▼$30.2752-Week Range$26.32▼$42.72Volume291,606 shsAverage Volume411,556 shsMarket Capitalization$18.36 billionP/E Ratio23.14Dividend YieldN/APrice Target$49.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Genmab A/S MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside77.3% Upside$49.25 Price TargetShort InterestBearish0.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 13 Articles This WeekInsider TradingN/AProj. Earnings Growth27.03%From $1.11 to $1.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.87 out of 5 starsMedical Sector353rd out of 904 stocksPharmaceutical Preparations Industry163rd out of 429 stocks 3.2 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 8 buy ratings, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageGenmab A/S has only been the subject of 3 research reports in the past 90 days.Read more about Genmab A/S's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.45% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Genmab A/S has recently increased by 7.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 2.1 News and Social Media Coverage News SentimentGenmab A/S has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Genmab A/S this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 27.03% in the coming year, from $1.11 to $1.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 23.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.54.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 23.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 119.12.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.04. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad HedgeyeNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY About Genmab A/S Stock (NASDAQ:GMAB)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Stock News HeadlinesJune 6 at 3:42 AM | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Price Target Raised to $53.00June 5 at 12:51 PM | globenewswire.comGenmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 4, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Given "Buy" Rating at HC WainwrightJune 3, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramJune 3, 2024 | businesswire.comInvestigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)June 3, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Hold" by AnalystsJune 2, 2024 | businesswire.comPreliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular LymphomaJune 1, 2024 | globenewswire.comInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)May 27, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMay 23, 2024 | finanznachrichten.deGenmab A/S: Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | globenewswire.comGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | businesswire.comGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 21, 2024 | businesswire.comGenmab Completes Acquisition of ProfoundBioMay 21, 2024 | globenewswire.comGenmab Completes Acquisition of ProfoundBioMay 21, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMay 20, 2024 | investorplace.com7 Biotech Stocks That Could Breathe New Life Into Your PortfolioMay 15, 2024 | finance.yahoo.comMarket Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'May 14, 2024 | businesswire.comGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressMay 13, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMay 7, 2024 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseMay 3, 2024 | markets.businessinsider.comOptimistic Outlook for Genmab: Strategic Growth and Product Performance Underpin Buy RatingMay 3, 2024 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call TranscriptMay 2, 2024 | seekingalpha.comGenmab A/S 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | globenewswire.comGenmab Announces Financial Results for the First Quarter of 2024May 1, 2024 | seekingalpha.comGenmab: A Complicated TaleSee More Headlines Company Calendar Last Earnings5/02/2024Today6/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees2,204Year Founded1999Price Target and Rating Average Stock Price Target$49.25 High Stock Price Target$53.00 Low Stock Price Target$46.00 Potential Upside/Downside+77.3%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$1.20 Trailing P/E Ratio23.14 Forward P/E Ratio25.02 P/E Growth1.04Net Income$631.91 million Net Margins30.74% Pretax Margin39.74% Return on Equity18.90% Return on Assets16.83% Debt Debt-to-Equity RatioN/A Current Ratio12.46 Quick Ratio12.42 Sales & Book Value Annual Sales$2.39 billion Price / Sales7.68 Cash Flow$1.21 per share Price / Cash Flow23.03 Book Value$6.95 per share Price / Book4.00Miscellaneous Outstanding Shares661,230,000Free Float651,047,000Market Cap$18.36 billion OptionableOptionable Beta0.99 Social Links Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.9MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.03MMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.14MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $637.57kMr. Christopher Cozic (Age 45)Executive VP & Chief People Officer Comp: $782.47kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $695.53kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $115.92kDr. Judith V. Klimovsky M.D. (Age 66)Executive VP & Chief Development Officer Comp: $1.17MDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.12MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $159.39kMore ExecutivesKey CompetitorsTakeda PharmaceuticalNYSE:TAKAlnylam PharmaceuticalsNASDAQ:ALNYTeva Pharmaceutical IndustriesNYSE:TEVARoyalty PharmaNASDAQ:RPRXBioMarin PharmaceuticalNASDAQ:BMRNView All CompetitorsInstitutional OwnershipAtria Investments IncSold 13,398 shares on 5/21/2024Ownership: 0.005%Dynasty Wealth Management LLCBought 13,472 shares on 5/16/2024Ownership: 0.002%Bayesian Capital Management LPBought 11,436 shares on 5/16/2024Ownership: 0.002%Bamco Inc. NYSold 66,714 shares on 5/15/2024Ownership: 0.011%Mount Yale Investment Advisors LLCBought 9,113 shares on 5/15/2024Ownership: 0.001%View All Institutional Transactions GMAB Stock Analysis - Frequently Asked Questions Should I buy or sell Genmab A/S stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares. View GMAB analyst ratings or view top-rated stocks. What is Genmab A/S's stock price target for 2024? 13 brokers have issued 12-month price targets for Genmab A/S's stock. Their GMAB share price targets range from $46.00 to $53.00. On average, they anticipate the company's share price to reach $49.25 in the next year. This suggests a possible upside of 77.3% from the stock's current price. View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts. How have GMAB shares performed in 2024? Genmab A/S's stock was trading at $31.84 on January 1st, 2024. Since then, GMAB shares have decreased by 12.8% and is now trading at $27.77. View the best growth stocks for 2024 here. Are investors shorting Genmab A/S? Genmab A/S saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,960,000 shares, an increase of 7.6% from the April 30th total of 2,750,000 shares. Based on an average daily volume of 520,800 shares, the short-interest ratio is currently 5.7 days. Currently, 0.5% of the shares of the stock are short sold. View Genmab A/S's Short Interest. When is Genmab A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our GMAB earnings forecast. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) issued its quarterly earnings data on Thursday, May, 2nd. The company reported $0.16 EPS for the quarter, meeting analysts' consensus estimates of $0.16. The company earned $603.30 million during the quarter, compared to analyst estimates of $594.23 million. Genmab A/S had a trailing twelve-month return on equity of 18.90% and a net margin of 30.74%. What ETFs hold Genmab A/S's stock? ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), iShares Biotechnology ETF (IBB), B.A.D. Etf (BAD), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and WisdomTree BioRevolution Fund (WDNA).Goldman Sachs Future Health Care Equity ETF (GDOC). What guidance has Genmab A/S issued on next quarter's earnings? Genmab A/S issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO). When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital International Investors (0.66%), Oppenheimer Asset Management Inc. (0.03%), Raymond James & Associates (0.03%), US Bancorp DE (0.02%), Williams Jones Wealth Management LLC. (0.01%) and Bamco Inc. NY (0.01%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GMAB) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTime is Running Out - June 25th Deadline Approaching!If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Genmab A/S You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.